Vemurafenib-induced bilateral facial palsy

The United States Food and Drug Administration (FDA) approved Vemurafenib in August 2011, for treatment of melanoma with BRAF V600 mutation. It has shown improvement in the median overall survival of melanoma patients. The most common adverse effects of vermurafenib are arthralgia, rash, alopecia, p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of postgraduate medicine 2014-04, Vol.60 (2), p.187-188
Hauptverfasser:	Shailesh, F N U, Singh, M, Tiwari, U, Hutchins, L F
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Case studies Causes of Complications and side effects Facial Paralysis - chemically induced Humans Indoles - administration & dosage Indoles - adverse effects Kinases Lyme disease Male Medical imaging Melanoma Melanoma - drug therapy Melanoma - genetics Melanoma - pathology Middle Aged Mutation Neoplasm Metastasis - drug therapy NMR Nuclear magnetic resonance Paralysis, Facial Positron-Emission Tomography Prednisone - therapeutic use Proto-Oncogene Proteins B-raf - genetics Skin - pathology Skin Neoplasms - drug therapy Skin Neoplasms - genetics Skin Neoplasms - pathology Sulfonamides - administration & dosage Sulfonamides - adverse effects Tomography Treatment Outcome Vemurafenib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!